Download Skin Diseases and the Eye - Texas Optometric Association

Dermatology
Skin Diseases
and the Eye








5th Edition
Wolff, Johnson, Suumond
2005
1000+ pages
857 photographs
largest organ; one of heaviest
Percent of total body weight??



Reference
Fitzpatrick’s Color Atlas and Synopsis of
Clinical Dermatology
Skin:
k
Just the
h facts
f

Tammy P. Than, MS, OD, FAAO
UAB School of Optometry
[email protected]
COPE #28424#28424-SD

Study of skin, its structure, functions, and
diseases
12--15%
12
20% of GP visits
1-2% of world population has psoriasis
Skin: The Layers




Epidermis
Dermis
Subcutaneous Fat
Integumentary
System
Epidermis







Stratum
Germinativum
Stratum Spinosum
Stratum Granulosum
(Stratum Lucidum
Lucidum))
Stratum Corneum
Langerhans Cells
 similar structurally to
melanocyte
 “macrophage of epidermis”
Merkel Cells
 touch receptors
1
Dermis




Connective tissue
Deep to epidermis
Supports epidermis
Two Parts


Subcutaneous Fat





Papillary dermis
Reticular dermis

Deep to dermis
Made up of lipocytes
Variable thickness
Functions:


Langer’s Lines
Epidermal Appendages

Hair Follicles





Epidermal Appendages

Hair Erector Muscles

Sebaceous Glands


No new follicles after birth
Growth is Cyclic




lanugo
vellus
terminal
Anagen Phase
Catagen Phase
Telogen Phase
90% of scalp hair is in growth phase








nail plate does not desquamate
Continuous growth (0.1 mm /d)
0.5
0
5–0
0.75
5 mm thick
function:
protection
scratching
 Grasping



Diagnostic!!
Pale nail bed – anemia
 White nails – liver disease
sebum
usually attached to hairs but can be free
sweat glands
most on palms, soles, axillae
Apocrine Glands
Dermal Appendages
Nails

“goose bumps”
Eccrine Glands
Epidermal Appendages

Insulation
Shock absorber
Nutritional depot

Blood vessels (reticular)





Superficial and deep plexus
Originate from subcutaneous fat
flow exceeds nutritional demand
Lymphatics
Nerves



Somatic sensory
Autonomic motor
Specialized end organs

2
Factitious Dermatosis




self-inflicted via mechanical, chemical, or
selfthermal
Differs from Munchausen’s syndrome
F >> M
shape of lesion may be bizarre





predominate on one side
may persist for years
R/O other causes!!
patient MAY appear normal
management:
Rosacea

>14 million Americans



unknown etiology

NOT related to sebum formation
Demodex folliculorum and Demodex brevis

Helicobacter pylori?


78% of Americans – no knowledge of disease
52% with rosacea – avoid public contact
2 factors


vascular changes
acneform eruptions


Rosacea



30-50 years of age
30F > M (3:1)
light complexion
Rosacea – Subjective




cosmesis
painful
facial heat
exacerbated by:



heat
alcohol
ocular complaints

up to 58% have ocular involvement
Trigger Factors?
Rosacea – Objective








Sun exposure (81%)
Emotional Stress (79%)
Hot weather (75%)
Wind (57%)
Heavy exercise (56%)
Alcohol consumption (52%)
Hot baths (51%)
inflammatory infiltration of upper dermis
no comedones
Stage 1

intermittent flushing
permanent erythema

telangiectasia


Stage 2

Stage 3

papules
pustules

rhinophyma


Stage 4
3
Ocular Rosacea


Subjective
Objective








Alodox


blepharitis
meibomianitis
conjunctivitis
episcleritis
iritis
chalazion
corneal changes
RCE (up to 15%)

Cynacon / Ocusoft
20 mg doxycycline
Alodox Convenience Kit



20 mg doxycycline
Lid scrubs
Tranquileyes Moist Heat Therapy Goggles


Thermoeyes reusable heat packs
Eye Eco Inc.
Nutridox


Advanced Vision Research
Meibomian gland health and therapy



Doxycycline
 75 mg
TheraTears Nutrition
 Fish oil (EPA 450 mg; DHA 300 mg)
 Flaxseed oil 1000 mg
 Vitamin E 183 IU
 3 gel caps qAM
iHeat Warm Compress System
Oracea

40 mg doxycycline capsules






q
qd
CollaGenex Pharmaceuticals
“Efficacy beyond 16 weeks and safety
beyond 9 months have not been
established”
$$ ($230 for 30 d)
Doxycycline

Side Effects:

GI discomfort
phototoxicity
reversible increased intracranial hypertension
superinfections
not for use in children
reduced efficacy of birth control pills

Secondary yeast infection






informed consent!
consent!
30 mg instant
10 mg sustained release
Rosacea - Treatment

metronidazole 0.75% gel


Finacea® (azelaic acid 15%) gel




bid x 9 weeks
Bid x 12 weeks
topical steroids
argon laser
dermabrasion
4
Final Words on Rosacea

Prognosis



Seborrheic Dermatitis

chronic
characteristic patterns
unknown etiology
gy

dry form

oily form

duration varies
can recur
eventually goes away (years)




Seborrheic Dermatitis



M>F
more in winter
Subjective
j



Infants


+/- pruritis
+/ocular complaints





Face and trunk



steroid cream
ketoconazole cream (Nizoral
(Nizoral))
Salicylic acid
Seborrheic Dermatitis – Management

Scalp treatment


selenium sulfide (Selsun
(Selsun Blue)
tar preps (Denorex, T/Gel, Tegrin
Tegrin))
 zinc pyrithione (Head & Shoulders)

Face and trunk

Rx
Akurza
Salex
 Keralyt (gel)
selenium sulfide (Selsun
(Selsun Blue)
tar preps (Denorex, T/Gel, Tegrin
Tegrin))
 zinc pyrithione (Head & Shoulders)
ionil
Neutrogena Healthy Scalp
Salicylic Topical (6%)
greasy scales with erythematous base
Scalp treatment

head, presternal area
Salicylic Acid Shampoo (2%)



“Cradle Cap”
Salicyclic Acid
small powdery scales
Seborrheic Dermatitis – Management
Adults

Pityrosporon ovale??





steroid cream
ketoconazole cream (Nizoral
(Nizoral))
Salicylic acid
Eyelids
5
Atopic Dermatitis





Chronic, relapsing
Not allergic
PHx or FHx of atopy
“the itch that rashes”
Etiology?

Mastrota Meibomian Paddle

- CYNACON/OcuSoft
- www.ocusoft.com
IgE
abnormal cellcell-mediated immune response
Atopic Dermatitis




onset usually between 2 mo and 1 year
M>F
duration: 1515-20 years
y
associated conditions





Acute



asthma
hay fever
subjective:

Atopic Dermatitis


PRURITIS!!
low cutaneous threshold for drying and itching
erythema
excoriation
papules / vesicles
secondary infections
Chronic

lichenification
Atopic Dermatitis

Infants (2 mo – 2 years)



chest, face, scalp, neck
less exudative
Older Children / Adults


lichenification
flexural areas

antecubital, popliteal, neck, periocular
Exacerbating Factors


Children ((< 10 years)


Atopic Dermatitis

foods / irritants
stress / temperature changes
Management

preventive





constant temperature
low humidity
hydration (Eucerin
(Eucerin))
tar preps
topical steroids
6
Atopic Dermatitis – Ocular
Atopic Dermatitis – Management








systemic
steroids
antibiotics
antihistamines
hospitalization
minimize stress
relocate!





scaling around eyes
Dennie--Morgan line
Dennie
“Allergic Shiner”
conjunctivitis
corneal involvement
Cataracts



asc and psc
keratoconus
retinal detachment

Complication of cataract sx
Atopic Dermatitis – Management of Ocular
Manifestations


Cool compresses / decongestants
topical (lots of options!!)





antihistamine
mast cell stabilizers
Combos
NSAIDs
steroids
Bepreve ®





BAK
Bid
Category C
≥ 2 YO
2.5, 5, 10 mL
Newest… 9/8/2009






Bepreve ®
Bepotastine besilate 1.5%
ISTA Pharmaceuticals
Antihistamine + mast cell stabilizer
Inhibits eosinophil chemotaxis
IND: allergic conjunctivitis - itching
Skin Treatment

Elidel cream ((pimecrolimus
pimecrolimus))







skin selective inflammatory cytokine inhibitor
Relatively new NSAID topical for atopic dermatitis
safe for >2 YO
can apply to lids
similar
i il -> Protopic
P t i
FDA Black Box Warning
Cutivate 0.1% ((fluticasone
fluticasone))




mid-level potency steroid cream
midsafe for >3 months
no reports of skin thinning
recommended 2 weeks or less
7
Impetigo






superficial skin infection
Staph aureus and/or Strep pyogenes
children and young adults
humid or poor hygiene
contagious
self--limiting but…
self
Vesicular Impetigo







“Impetigo”
vesicles/pustules -> rupture -> crust
erythema
face and extremities
pruritus
+/-- lymphadenopathy
+/
afebrile
Bullous Impetigo




Staph aureus
vesicle -> bullae -> crust
no erythema
extremities, face, trunk
Impetigo

Lab testing



Gm stain
culture
Treatment

improve hygiene (Hibiclens
(Hibiclens))






Impetigo

Treatment


systemic antibiotics
treat eye as necessary
http://hibiclens.com/default.html
remove crusts
topical antibiotics
bacitracin or erythromycin
mupirocin 2% tid (Bactroban)
Bactroban)
treat nares
Ocular TRUST


Ocular Tracking Resistance in U.S
U.S.. Today
The only longitudinal nationwide
antimicrobial susceptibility surveillance
program specific to ocular isolates

S aureus
S.





MRSA
MSSA
Coagulase--negative Staph
Coagulase
S. pneumoniae
H. influenzae
Asbell PA, Sahm DF. Longitudinal nationwide antimicrobial susceptibility
surveillance in ocular isolates. Results of Ocular TRUST 2. ARVO 2008.
8
Ocular TRUST: Participating
Sites
Ocular TRUST 2:
Susceptibility Testing

In vitro susceptibility testing to nine
antimicrobials



State with
participating
institution
Participating
Eye Centers
(10)






MSSA
Coagulase--Negative Staphylococci (CNS)
Coagulase
ciprofloxacin
levofloxacin
gatifloxacin
moxifloxacin
azithromycin
trimethoprim
tobramycin
polymyxin B
penicillin
MRSA
Coagulase--Negative Staphylococci (CNS)
Coagulase
9
Streptococcus pneumoniae
Psoriasis







2-8 million people in US
chronic, unpredictable disease
disorder of proliferation and inflammation
erythematous,, scaly plaque
erythematous
F=M
dominant transmission
association with arthritis
Psoriasis




unknown etiology
increase mitosis
enlarged,
enlarged tortuous dermal capillaries
can be exacerbated by precipitating
factors


Psoriasis






trauma
stress

initially – red scaling papules
eventually



round to oval p
plaque
q
adherent silvery, white scale
extensor sites (elbows, knees)
scalp
lumbosacral area
nails
Subjective:



Psoriasis – Objective

Location
cosmesis
20% have pruritis
+/-- joint pain
+/
Plaque Psoriasis



most common
enlarge to certain, stable size
may have residual macule
Koebner reaction

traumatized normal skin develops
psoriatic lesions
10
Psoriatic Arthritis
Psoriasis – Management



nail involvement in 80%






pitting
discoloration
oncholysis
30-50 yo
30F>M

Minimize precipitating factors
Reassurance
“Psoriasis Therapeutic Ladder”
 lubricants, emollients
 tar cpds
 topical steroids
 Salicylic acid
 PUVA
Two--tiered approach
Two
 Localized therapy
 Systemic and/or phototherapy
Psoriasis – Ocular Complications



Tear film (decreased TBUT, MGD)
Eyelid – blepharitis,
blepharitis, trichiasis
trichiasis,, ectropion
Conjunctiva
j
/ Cornea



Acanthosis nigricans



conjunctivitis, KCS, symblepharon
diffuse, velvety thickening and
hyperpigmentation of the skin
axillae,, other body folds, neck, periocular
axillae
etiology
gy

Nodular episcleritis
Anterior uveitis

heredity
endocrine disorders





associated with insulin resistance
Polycystic ovary syndrome
obesity
drug administration
malignancy
Acanthosis nigricans

Testing

Medications






rule out diabetes, hypothyroidism
Retin-A
Retin15% urea
alpha--hydroxy acid
alpha
salicylic acid
Prognosis



hereditary – may regress when older
may regress with weight loss
discontinue causative drug will cause resolution
11
Scleroderma

connective tissue disease





Scleroderma – Two Forms

fibrosis
Diffuse – 60%

progressive
autoimmune
F > M (4:1)
30--50 YO at onset
30

Limited (CREST) – 20%






Scleroderma


Raynaud’s phenomenon – usually first
cutaneous disease



thickened skin
loss of facial expression / swollen look


esophagus
lungs
kidneys
heart



3 Stages



Stage 1: pallor
Stage
g 2: cyanosis
y
Stage 3: hyperemia
up to 20%
precipitating factors: cold, stress, smoking
PHENOMENON when associated with other
disease or other cause:

Raynaud’s Disease

episodic constriction of digital arteries
usually F

internal organs

Calcinosis
Raynaud’s phenomenon
Esophageal
Sclerodactyly
Telangiectases
CRST, ST, etc.
Raynaud’s Disease


systemic scleroderma
rheumatic disorders, drugs, carpel tunnel
syndrome
Scleroderma – Ocular







+/- ptosis; +/+/+/- lagophthalmos
KCS
mucous filaments
telangiectasia
cataracts
uveitis
HTN retinopathy
12
Alopecia Areata
Scleroderma – Management



treat Raynaud’s phenomenon
steroids
ocular:





lubricants
ointments
tape
ptosis crutch
punctal occlusion





different than androgenetic alopecia
non--inflammatory
non
inflammatory,, nonnon-scarring hair
loss
idiopathic
M=F
children and young adults
Alopcia Areata




well demarcated areas (1(1-4 cm)
skin is normal
exclamation points (hallmark)
Sites:




Scalp
Beard
eyebrows
Alopecia Areata



Alopecia totalis
Alopecia universalis
DDX:



Management:

+/-- “hammered brass” nails
+/
fungal infections
secondary syphilis

Prognosis
Therapy
Trichotillomania

Self--inflicted alopecia
Self
Latisse™
Latisse
™




Fractured hairs of unequal lengths
may need therapy


Allergan (Medical Aesthetics)
Approved 12/2008
0 03% bimatoprost
0.03%
Indication:


Hypotrichosis of eyelashes
Caution:


Active intraocular inflammation
Aphakia,, risk factors for CME
Aphakia
13